184 related articles for article (PubMed ID: 30027061)
1. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker.
Chung SW; Choi JU; Cho YS; Kim HR; Won TH; Dimitrion P; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Adv Sci (Weinh); 2018 Jul; 5(7):1800368. PubMed ID: 30027061
[TBL] [Abstract][Full Text] [Related]
2. Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC.
Kim HR; Cho YS; Chung SW; Choi JU; Ko YG; Park SJ; Kim SY; Byun Y
J Control Release; 2022 Jun; 346():136-147. PubMed ID: 35447298
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
Doloff JC; Su T; Waxman DJ
BMC Cancer; 2010 Sep; 10():487. PubMed ID: 20836875
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
Schwartz PS; Chen CS; Waxman DJ
Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.
Hunt MA; Li D; Hay MP; Currie MJ; Robinson BA; Patterson AV; Dachs GU
J Gene Med; 2012 Jan; 14(1):62-74. PubMed ID: 22147660
[TBL] [Abstract][Full Text] [Related]
6. Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer.
Cho YS; Kim HR; Park SJ; Chung SW; Ko YG; Yeo JH; Lee J; Kim SK; Choi JU; Kim SY; Byun Y
Biomaterials; 2022 Oct; 289():121783. PubMed ID: 36084486
[TBL] [Abstract][Full Text] [Related]
7. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
[TBL] [Abstract][Full Text] [Related]
8. Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.
Rajaputra P; Bio M; Nkepang G; Thapa P; Woo S; You Y
Bioorg Med Chem; 2016 Apr; 24(7):1540-9. PubMed ID: 26928287
[TBL] [Abstract][Full Text] [Related]
9. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
10. The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer.
Sato T; Neschadim A; Lavie A; Yanagisawa T; Medin JA
PLoS One; 2013; 8(10):e78711. PubMed ID: 24194950
[TBL] [Abstract][Full Text] [Related]
11. Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy.
Lee BS; Cho YW; Kim GC; Lee DH; Kim CJ; Kil HS; Chi DY; Byun Y; Yuk SH; Kim K; Kim IS; Kwon IC; Kim SY
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505252
[TBL] [Abstract][Full Text] [Related]
12. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.
Lumniczky K; Sáfrány G
Pathol Oncol Res; 2006; 12(2):118-24. PubMed ID: 16799716
[TBL] [Abstract][Full Text] [Related]
13. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.
Chung SW; Choi JU; Lee BS; Byun J; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Biomaterials; 2016 Jul; 94():1-8. PubMed ID: 27085176
[TBL] [Abstract][Full Text] [Related]
14. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013; 3():263. PubMed ID: 24109591
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis.
Sato T; Neschadim A; Nakagawa R; Yanagisawa T; Medin JA
Methods Mol Biol; 2015; 1317():55-67. PubMed ID: 26072401
[TBL] [Abstract][Full Text] [Related]
16. Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.
Cho YS; Kim GC; Lee HM; Kim B; Kim HR; Chung SW; Chang HW; Ko YG; Lee YS; Kim SW; Byun Y; Kim SY
J Control Release; 2022 Apr; 344():26-38. PubMed ID: 35202743
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
18. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
Denny WA; Wilson WR
J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
[TBL] [Abstract][Full Text] [Related]
19. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
20. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
